Skip to main content
Bildspel: 

Phase 2-results for BUPI published

STOCKHOLM, August 31st 2017, Moberg Pharma AB (OMX: MOB) announces that the results from a phase 2-study with BUPI for the treatment of pain due to oral mucositis in patients with head and neck cancer have been published in the journal Pain Reports.

Early 2016, Moberg Pharma announced positive top-line results from a phase 2-study with BUPI, showing that BUPI (a patent pending lozenge with bupivacaine) achieved a statistically significant reduction in pain in the oral cavity compared to standard treatment. The results are now published in the journal Pain Reports and are available online. 

Key findings include:

  • The primary endpoint, that was met with high statistical significance, was a measurement of pain in the mouth or pharynx, 60 minutes post administration of BUPI, compared to the average pain during the day for the control group. The group treated with BUPI had 31% reduction in pain compared to the control group (p=0,0032). Both groups were allowed to use standard treatment options for pain during the study. The control group was furthermore allowed to use locally acting anesthetics for the oral cavity, in the form of a lidocaine gel.
  • When the effect in the mouth, excluding the pharynx, was measured, the difference between the groups was even more pronounced. Treatment with BUPI resulted in an additional pain reduction of 50% compared to standard treatment (p=0,0002).

For the full article, see:

http://journals.lww.com/painrpts/Abstract/latest/Effect_of_bupivacaine_lozenges_on_oral_mucositis.99956.aspx

About this information
The information was submitted for publication, through the agency of the contact person set out above, at 8.00 a.m. (CET) on September 1st 2017.

For additional information, please contact:
Peter Wolpert, CEO, telephone: +46 70 735 71 35, e-mail: peter.wolpert@mobergpharma.se
Anna Ljung, CFO, telephone: +46 707 66 60 30, E-mail: anna.ljung@mobergpharma.se

About Moberg Pharma, www.mobergpharma.com
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the U.S. and a distributor network in more than 40 countries. The company’s portfolio includes the OTC brands Kerasal®, Kerasal Nail®, Balmex®, New Skin®, Dermoplast®and Domeboro®. Kerasal Nail® (Emtrix®, Zanmira® or Nalox™ in certain markets) is a leading OTC treatment of nail disorders in the U.S., Canada as well as in several markets in EU and Southeast Asia. The company is growing organically as well as through acquisitions. Internal development programs focus on innovative drug delivery of proven compounds and include two assets in late-stage clinical development, MOB-015 (onychomycosis) and BUPI (pain management in oral mucositis). Moberg Pharma has offices in Stockholm and New Jersey and the company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).